Amgen and Allergan Submit BLA for Avastin® Biosimilar

Biosimilar News

As we previously reported, Amgen and Allergan are currently collaborating on four oncology biosimilars, including an Avastin® (bevacizumab) biosimilar, ABP 215.

Yesterday, the companies announced the submission of a Biologics License Application (BLA) to FDA for ABP 215.  According to the announcement, Amgen and Allergan believe theirs is the first BLA for a bevacizumab biosimilar submitted to FDA.

The full press release from Amgen and Allergan can be found here.

Download PDF

Comments are closed.